Clinical Trials | December 31, 2025
GenSight Biologics gets early access nod for candidate gene therapy in Israel
Applications include detailed scientific rationale and supporting clinical evidence
Applications include detailed scientific rationale and supporting clinical evidence
The applications aim to launch Phase Ib/II trials for relapsed/refractory multiple myeloma and primary plasma cell leukemia, respectively
The agreement to sell B Medical Systems marks a major step forward in simplifying the portfolio to prioritize our core capabilities with the highest strategic impact
The interim efficacy readout, involving around 170 participants with 15-month data, remains on track for the end of March 2026
Transcenta will grant EirGenix a non-exclusive license to its Highly Intensified Continuous Bioprocessing (HiCB) platform
The company plans to use the newly secured funding to expand the indications of its Grabody platform into high-unmet-need areas
Despite some promising subgroup signals, the company indicated it will not pursue further psychiatric trials
The plant is expected to enhance regional supply capabilities
Astal estimates the collaboration will generate incremental revenue of approximately Rs. 300 crore upon implementation
CIRRUS-HCM, an open-label, multi-part study, evaluates EDG-7500 in patients with obstructive and nonobstructive HCM
Subscribe To Our Newsletter & Stay Updated
